Relationship between lunasin's sequence and its inhibitory activity of histones H3 and H4 acetylation

Molecular Nutrition and Food Research

Volumn 55, Issue 7, 2011, Pages 989-998

  Hernández Ledesma, Blanca ^a,b   Hsieh, Chia Chien ^a   De Lumen, Ben O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF FOOD SCIENCE RESEARCH CIAL   (Spain)

Author keywords

Breast cancer cells; Cell proliferation; Histone acetylation; Lunasin; Protein biomarkers

Indexed keywords

BIOLOGICAL MARKER; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLINE; ENZYME INHIBITOR; GM2S 1 PROTEIN, GLYCINE MAX; GM2S-1 PROTEIN, GLYCINE MAX; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; LYSINE; P300-CBP-ASSOCIATED FACTOR; PEPTIDE FRAGMENT; SOYBEAN PROTEIN;

ACETYLATION; AMINO ACID SEQUENCE; ARTICLE; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IC 50; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ACETYLATION; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLINS; ENZYME INHIBITORS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; LYSINE; MOLECULAR SEQUENCE DATA; P300-CBP TRANSCRIPTION FACTORS; PEPTIDE FRAGMENTS; SOYBEAN PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959947667     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000632     Document Type: Article

References (43)

1. Fog, C. K., Jensen, K. T., Lund, A. H., Chromatin-modifiying proteins in cancer. APMIS 2007, 115, 1060-1089.
2. Goldberg, A. D., Allis, C. D., Bernstein, E., Epigenetics: a landscape takes shape. Cell 2007, 128, 635-638.
3. Kornberg, R. D., Lorch, Y. L., Twenty-five years of the nucleosome, fundamental particle of the eukaryotic chromosome. Cell 1999, 98, 285-294.
4. Li, B., Carey, M., Workman, J. L., The role of chromatin during transcription. Cell 2007, 128, 707-719.
5. Dwarakanath, B. S., Verma, A., Bhatt, A. N., Parmar, V. S., Raj, H. G., Targeting protein acetylation for improving cancer therapy. Ind. J. Med. Res. 2008, 128, 13-21.
6. Strahl, B. D., Allis, C. D., The language of covalent histone modifications. Nature 2000, 403, 41-45.
7. Lehrmann, H., Pritchard, L. L., Harel-Bellan, A., Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 2002, 86, 41-65.
8. Muraoka, M., Konishi, M., Kikuchi-Yanshita, R., Tanaka, K. et al., p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12, 1565-1569.
9. Gayther, S. A., Batley, S. J., Linger, L., Bannister, A. et al., Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24, 300-303.
10. Ionov, Y., Matsui, S. I., Cowell, J. K., A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc. Natl. Acad. Sci. USA 2004, 101, 1273-1278.
11. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., Kundu, T. K., Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 2003, 278, 19134-19140.
12. Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V. et al., Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279, 33716-33726.
13. Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V. et al., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferasedependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
14. Chol, K. C., Lee, Y. H., Jung, M. G., Kwon, S. H. et al., Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol. Cancer Res. 2009, 7, 2011-2021.
15. Galvez, A. F., de Lumen, B. O., A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells. Nat. Biotechnol. 1999, 17, 495-500.
16. Hernández-Ledesma, B., Hsieh, C. C., de Lumen, B. O., Lunasin, a novel peptide for cancer prevention. Peptides 2009, 30, 426-430.
17. Galvez, A. F., Chen, N., Macasieb, J., de Lumen, B. O., Chemopreventive property of a soybean peptide (Lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res. 2001, 61, 7473-7478.
18. Lam, Y., Galvez, A. F., de Lumen, B. O., Lunasin suppresses E1A-mediated transformation of mammalian cells but does not inhibit growth of immortalized and established cancer cell lines. Nutr. Cancer 2003, 47, 88-94.
19. Hsieh, C. C., Hernandez-Ledesma, B., de Lumen, B. O., Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS One 2010, 5, e8890.
20. Hsieh, C. C., Hernández-Ledesma, B., de Lumen, B. O., Seed peptide lunasin suppresses in vitro and in vivo 7, 12-dimethylbenz[a]anthracene-induced tumorigenesis. J. Food Sci. 2010, 75, H311-H316.
21. Hernández-Ledesma, B., Hsieh, C. C., de Lumen, B. O., Anti-inflammatory and antioxidant properties of peptide lunasin in RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 2009, 390, 803-808.
22. Hsieh, C. C., Hernández-Ledesma, B., de Lumen, B. O., Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced-apoptosis. Chem. Biol. Interact. 2010, 186, 127-134.
23. Jeong, J. B., Jeong, H. J., Park, J. H., Lee, S. H. et al., Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb). J. Agric. Food Chem. 2007, 55, 10707-10713.
24. Jeong, H. J., Jeong, J. B., Kim, D. S., de Lumen, B. O., Inhibition of core histone acetylation by the cancer preventive peptide lunasin. J. Agric. Food Chem. 2007, 55, 632-637.
25. Seo, S. B., Macfarlan, T., McNamara, P., Hong, R. et al., Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J. Biol. Chem. 2002, 277, 14005-14010.
26. Kuninger, D., Lundblad, J., Semirale, A., Rotwein, P., A non-isotopic in vitro assay for histone acetylation. J. Biotechnol. 2007, 131, 253-260.
27. Fan, Z., Zhang, H., Zhang, Q., Tumor suppressor pp32 represses cell growth through inhibition of transcription by blocking acetylation and phosphorylation of histone H3 and initiating its proapoptotic activity. Cell Death Differ. 2006, 13, 1485-1494.
28. Yu, Q. Y., Sicinski, P., Mammalian cell cycles without cyclin E-CDK2. Cell Cycle 2004, 3, 292-295.
29. Dalvai, M., Bystricky, K., The role of histone modifications and variants in regulating gene expression in breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15, 19-33.
30. Davie, J. R., Samuel, S. K., Spencer, V. A., Holth, L. T. et al., Organization of chromatin in cancer cells: role of signalling pathways. Biochem. Cell Biol. 1999, 77, 265-275.
31. Roth, S. Y., Denu, J. M., Allis, C. D., Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
32. Mai, A., Massa, S., Rotili, D., Cerbara, I. et al., Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25, 261-309.
33. Eliseeva, E. D., Valkov, V., Jung, M., Jung, M. O., Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther. 2007, 6, 2391-2398.
34. Varier, R. A., Swaminathan, V., Balasubramanyam, K., Kundu, T. K., Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem. Pharmacol. 2004, 68, 1215-1220.
35. Fraga, M. F., Ballestar, E., Villor-Garea, A., Boix-Chornet, M. et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37, 391-400.
36. Elsheikh, S. E., Green, A. R., Rekha, E. A., Paish, E. C. et al., Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69, 3802-3809.
37. Seligson, D. B., Horvath, S., Shi, T., Yu, H. et al., Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435, 1262-1266.
38. Barlesi, F., Giaccone, G., Gallegos-Ruiz, M. I., Loundou, A. et al., Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 458-4564.
39. Park, Y. S., Jin, M. S., Kim, Y. G., Yook, J. H. et al., The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann. Surg. Oncol. 2008, 15, 1968-1976.
40. Im, J. Y., Park, H., Kang, K. W., Choi, W. S., Kim, H. S., Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem. Biol. Interact. 2008, 172, 235-244.
41. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., Sherr, C. J., Direct binding of cyclin-D to the retinoblastoma gene-product (pRB) and pRBb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993, 7, 331-342.
42. Sutherland, R. L., Musgrove, E. A., Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 2004, 9, 95-104.
43. 1-to-S transition. Am. J. Physiol. Cell Physiol. 2003, 284, C349-C364.